Related Article from Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib

Pasquale Lombardi, Jung Sun Kim, Giulia Francesca Manfredi, Ciro Celsa, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Bernardo Stefanini, Nidhi Doshi, Emily Warmington, Thomas U. Marron, Matthias Pinter, Bernhard Scheiner, Beodeul Kang, Ho Yeong Lim, Wei‐Fan Hsu, Brooke Wietharn, Marianna Silletta, Alessandro Parisi, Chun‐Yen Lin, Andrea Dalbeni, Gianluca Masi, Martin Schönlein, Johann von Felden,

Related Article from Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib

Abstract

Discussion(0)

Open reviews(0)

Related publications

Related Article from Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib

Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib

Data from Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib

Data from Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib

Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study